Note: The full article and accompanying features are only available whilst being signed in.
Summary
In the light of recent events, Alan Greenspan is reported to have said that a company’s value today may amount to its “capitalised reputation”.
In the wake of several high-profile controversies surrounding the influence and honesty of drug companies, confidence in the Pharmaceutical Industry is plummeting and corporate reputation is vulnerable to attack. This was illustrated by a sudden slide in AstraZeneca’s share price of 222p which reduced the company value by £3.7 Billion and GSK’s decline in value of £3 Billion in the wake of comments by David Graham during Senate hearings on the Vioxx case. But as Dr. Andrée Bates, of predictive mathematical analytics specialists - Eularis - explains, few Pharmaceutical companies have been able to accurately predict the actual extent to which their reputation and other corporate activities are likely to assist them or hinder them in marketing their brands, and the actual impact on their market share, before it is too late.
Want more?
The content of this page been summarized. To view the full content, please register or sign in to the Eularis web site.
Register with Eularis
or
Sign in